Markets

Obalon Therapeutics Inc. (OBLN), Interview with Dr. Andrew Rasdal, CEO

Watch the CEO Signature Series interview with Dr. Andrew Rasdal, Chief Executive Officer of Obalon Therapeutics Inc. (OBLN).

Dr. Andrew Rasdal, CEO

Dr. Andrew Rasdal, CEO

About Andrew Rasdal

Andrew Rasdal has served as our President and Chief Executive Officer and a member of our board of directors since June 2008. Mr. Rasdal brings more than 25 years of medical technology experience, including serving as CEO of DexCom, Inc., Senior Vice President and President of Vascular for Medtronic, Inc., and Vice President of Marketing for Arterial Vascular Engineering.

About Obalon Therapeutics Inc.

Obalon Therapeutics Inc. (Nasdaq: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Andy Rasdal, Chief Executive Officer of Obalon, will ring the Closing Bell.

Obalon Therapeutics, Inc. (Nasdaq: OBLN), is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

OBLN

Other Topics

Technology Leadership Investing